Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1073/pnas.0811559106">http://dx.doi.org/10.1073/pnas.0811559106</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>National Academy of Sciences</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sun Dec 16 06:10:18 EST 2018</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/50256">http://hdl.handle.net/1721.1/50256</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Thomas P. J. Garrett,a,1 Antony W. Burgessb,1,2 Hui K. Ganc, Rod B. Luworb, Glenn Cartwrightc, Francesca Walkerb, Suzanne G. Orchard, Andrew H. A. Claysb, Edouard C. Nice, Julie Rothackeb, Bruno Catimelb, Webster K. Caveneed, Lloyd J. Old, Elisabeth Stockertae,3 Gerd Rittere, Timothy E. Adamsb, Peter A. Hoyneb, Dane Wittrupb, Ginger Chao, Jennifer R. Cochranb, Cindy Luob, Mezhen Loua, Trevor Huystob, Yinbin Xub, W. Douglas Fairliea, Shenggen Yaoa, Andrew M. Scottb, and Terrance G. Johnsc,4

aWalter and Eliza Hall Institute of Medical Research, Parkville 3050, Australia; bLudwig Institute for Cancer Research, Melbourne Branch, Parkville 3050, Australia; cLudwig Institute for Cancer Research, Melbourne Centre, Heidelberg 3084, Australia; dLudwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92039-0660; eLudwig Institute for Cancer Research, New York, NY 10021-6007; Division of Molecular and Health Technologies, Commonwealth Scientific and Industrial Research Organisation, Parkville 3052, Australia; and Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139

Edited by Jerry M. Adams, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia and approved February 17, 2009

Received for review November 19, 2008

Epidermal Growth Factor Receptor (EGFR) is involved in stimulating the growth of many human tumors, but the success of therapeutic agents has been limited in part by interference from the EGFR on normal tissues. Previously, we reported an antibody (mab806) against a truncated form of EGFR found commonly in gliomas. Remarkably, it also recognizes full-length EGFR on tumor cells but not on normal cells. However, the mechanism for this activity was unclear. Crystallographic structures for Fab:EGFR287–302 complexes of mab806 (and a second, related antibody, mAb175) show that this peptide epitope adopts conformations similar to those found in the wtEGFR. However, in both conformations observed for wtEGFR, tethered and untethered, antibody binding would be prohibited by significant steric clashes with the CR1 domain. Thus, these antibodies must recognize a cryptic epitope in EGFR. Structurally, it appeared that breaking the disulfide bond preceding the epitope might allow the CR1 domain to open up sufficiently for antibody binding. The EGFR271A/C283A mutant not only binds mAb806, but binds with 1:1 stoichiometry, which is significantly greater than wtEGFR binding. Although mAb806 and mAb175 decrease tumor growth in xenografts displaying mutant, overexpressed, or autocrine stimulated EGFR, neither antibody inhibits the in vitro growth of cells expressing wtEGFR. In contrast, mAb806 completely inhibits the ligand-associated stimulation of cells expressing EGFR271A/C283A. Clearly, the binding of mAb806 and mAb175 to the wtEGFR requires the epitope to be exposed either during receptor activation, mutation, or overexpression. This mechanism suggests the possibility of generating antibodies to target other wild-type receptors on tumor cells.

cancer | cryptic | epitope | therapeutic antibody | structure

Epidermal Growth Factor Receptor (EGFR) activation is a feature of many cancers, but understanding how ligand activates the EGFR has been challenging. However, elegant genetic, biochemical, and crystallographic studies have revealed many of the complex series of conformational changes and aggregation events required to activate the EGFR intracellular tyrosine kinase domain (1, 2). Amidst these complexities, it is apparent that in solution the EGFR extracellular domain adopts at least 2 fundamental conformations: an inactive tethered conformation and an active untethered, or extended, ligand-bound “back-to-back” dimer.

Two major classes of agents have been developed to target the EGFR and prevent receptor activation: tyrosine kinase inhibitors (TKIs) and mAbs (3). TKIs, such as gefitinib and erlotinib, act by competitively binding to the ATP pocket of EGFR (3), whereas mAbs, such as cetuximab (4) and panitumumab (5), inhibit ligand binding. Both classes of agents display significant anti-tumor activity in a range of EGFR-dependent mouse xenograft models, and both have been approved for clinical use in selected cancer patients, including lung, head and neck, and colon cancers, where they display modest activity (3, 6–8). Although these therapeutics show promise, their use is restricted by antibody clearance by wtEGFR in the liver and dose-limiting toxicities, such as skin rash that results from significant uptake of these agents in normal skin where EGFR is expressed (9).

In most gliomas, over-expressed EGFR is associated with the expression of a truncated form of the receptor Δ2–7EGFR (10). The D2–7EGFR contains a unique N-terminal fusion peptide, resulting from the joining of exons 1 and 8. Monoclonal antibodies directed to this junctional peptide have been described (11) and represent potential therapeutics, specific for the tumors that express Δ2–7EGFR. We generated a panel of antibodies against the D2–7EGFR, using NR6 cells over-expressing this truncated EGFR as the immunogen. While binding to the D2–7EGFR, the 2 antibodies described here also bind the over-expressed wtEGFR on cancer cells (12, 13), but notably do not bind to wtEGFR on normal cells. EGFR over-expression and mutation occur in tumor cells but are rare in normal tissues. The results from our completed Phase I clinical trial with a radio-labeled, chimeric version of mab806 demonstrated that this antibody targets the EGFR on tumors (14). Interestingly, mAb806 also shows synergistic anti-tumor activity in animal models when used in combination with other EGFR therapeutics, including EGFR kinase inhibitors (15) and antibodies to unrelated EGFR epitopes (16). Physiologically and biochemically, this unusual specificity is consistent with the antibodies binding to a cryptic epitope, one not exposed in normal cells but recognizable on cancer cells. Exactly how this specificity is achieved has not been clear.

Epitope mapping studies showed that mAb806 binds a short cysteine loop comprising amino acids 287–302 of the extracellular domain (17). Inspection of crystal structures for this region of...
sensitive EGFR antibody mAb225 was used to confirm denaturation. Still recognized by the 9E10 anti-myc antibody in all cases, and the conformation—possibly R300), but that mAb175 appeared moderately more sensitive human EGFR in vivo, but not the wtEGFR when it is expressed at normal levels. mAb175 stained sections of A431 xenografts over-expressing wtEGFR and truncated human EGFR in vivo, but not the wtEGFR when it is expressed at normal levels. mAb175 stained sections of A431 xenografts over-expressing wtEGFR and U87MG cells that express the D2–7EGFR, but not the parental U87MG cells that express only 1 × 10^5 wtEGFR per cell or sections of normal human liver (Fig. S3). Yeast display of single site mutants within the epitope region showed that residues critical for mAb175 binding were the same for mAb806 (E293, G298, V299, C302 and possibly R300), but that mAb175 appeared moderately more sensitive to mutations at V299 and D297 (Fig. S1B).

The affinity of mAb175 for EGFR\_273–302 ranged from 35 nM (Pms-serine coupling) to 154 nM (amine coupling), but, in all cases, the binding affinity of mAb175 for the EGFR\_287–302 peptide was lower than that obtained for mAb806 (Table 1). Conversely, mAb175 bound receptor fragments 1–501 and 1–621 with higher affinity than mAb806 (16 nM vs. 35 nM and 188 nM vs. 389 nM, respectively) (Table 1). For each antibody, the affinity for the full-length extracellular domain, EGFR\_1–621, that can form the tethered conformation was much lower than the untethered form.

**Efficacy of mAb806 and mAb175 Against Tumor Xenografts Stimulated by D2–7EGFR or an EGFR Autocrine Loop.** We compared the in vivo anti-tumor activity of mAb806 and mAb175 against U87MG.D2–7 glioma xenografts (Fig. 24). Xenografts were allowed to establish for 6 days, and the average tumor volume was 100 mm^3 before antibody therapy commenced. mAb175 treatment inhibited tumor growth more effectively than mAb806 treatment. The average tumor volumes on day 19 were 1530 ± 200 mm^3, 300 ± 30 mm^3, and 100 ± 10 mm^3 for the vehicle, mAb806, and mAb175 treatment groups, respectively (P < 0.001 for mAb175 vs. control and P < 0.002 for mAb175 vs. mAb806).

Even though U87MG cells express \( \sim 1 \times 10^5 \) endogenous wtEGFR per cell, mAb806 does not recognize any of the surface EGFR expressed or inhibit the growth of U87MG tumors in vivo

---

**Table 1. Antibody affinities for EGFR epitopes**

<table>
<thead>
<tr>
<th>EGFR fragment coupling</th>
<th>( K_o ) for mAb175, nM</th>
<th>( K_o ) for mAb806, nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>287–302 (Pms-Ser)</td>
<td>35 ± 6</td>
<td>16 ± 8</td>
</tr>
<tr>
<td>287–302 (Thiol)</td>
<td>143 ± 2</td>
<td>84 ± 3</td>
</tr>
<tr>
<td>287–302 (Amine)</td>
<td>154 ± 0.1</td>
<td>85 ± 0.3</td>
</tr>
<tr>
<td>1–501 (Amine)</td>
<td>16 ± 0.03</td>
<td>34 ± 0.03</td>
</tr>
<tr>
<td>1–621 (Amine)</td>
<td>188 ± 0.01</td>
<td>389 ± 0.01</td>
</tr>
</tbody>
</table>

*Unable to form tether.
Can form tether.

---

**Fig. 1.** Localization of the mAb175 epitope in EGFR. (A) Lysates from 293T cells transfected with vector control (EGFP) or vectors expressing the EGFR-GH fragment fusion proteins (GH-274–501, GH-282–501, GH-290–501, GH-298–501, and GH-Δ287–302) were resolved by SDS-PAGE, transferred to membrane, and immunoblotted with mAb175 (Upper) or the anti-myc antibody 9B11 (Lower). (B) Fragments of the EGFR were displayed on yeast and their reactivity with mAb175, mAb806, and 2 control antibodies determined by FACS. The epitope recognized by mAb175 is similar to that of mAb806 (Upper) and was not sensitive to denaturation by heating yeast pellets to 80 °C for 30 min (Lower). The c-myc tag was still recognized by the 9E10 anti-myc antibody in all cases, and the conformation-sensitive EGFR antibody mAb225 was used to confirm denaturation.

---

**Fig. 2.** Effects of mAb175 and mAb806 on glioma and prostate cancer xenografts. (A) Mice (n = 5) bearing U87MG.D2–7 xenografts were injected i.p. with PBS and 1 mg of mAb175 or mAb806 (positive control) on days 6, 8, 10, 13, 15, and 17 when the starting tumor volume was 100 mm^3. Data are expressed as mean tumor volume ± SE. (B) DU145 cells were stained with a negative control antibody (gray), mAbS28 for total EGFR (blue), mAb806 (orange), and mAb175 (green) and then analyzed by FACS. (C) DU145 cells were lysed; subjected to IP with mAbS28, mAb806, mAb175, or an independent irrelevant antibody (control); and then immunoblotted for EGFR (D) Mice (n = 5) bearing DU145 xenografts were injected i.p. with PBS and 1 mg of mAb175 or mAb806 daily on days 18–22, 25–29, and 39–43 when the starting tumor volume was 90 mm^3. Data are expressed as mean tumor volume ± SE.
U87MG cells do not appear to coexpress any EGFR ligand; however, there is evidence that mAb806 can recognize the EGFR when it is activated by ligand (18). Therefore, we tested whether the wtEGFR could be recognized by mAb806 or mAb175 in cells stimulated by an EGFR autocrine loop (21, 22), such as the prostate cell line DU145. These cells express the wtEGFR at levels similar to that observed in U87MG cells, but contain an amplification of the TGF-α gene (21) and therefore an EGFR/TGF-α autocrine loop. Both mAb175 and mAb806 bind to DU145 cells as determined by FACS analysis (Fig. 2B), and both antibodies are able to immunoprecipitate a small proportion of the EGFR extracted from these cells (Fig. 2C). In each case, mAb175 binds more effectively than mAb806.

Because mAb175 and mAb806 bind more effectively to the EGFR expressed in DU145 cells than U87MG cells, we analyzed the anti-tumor activity of these antibodies in DU145 xenografts grown in nude mice (Fig. 2D). Xenografts were allowed to establish for 18 days to an average tumor volume of 90 mm³. Therapy with 605 mAb806 recognize a subset of the wtEGFR molecules, crystal structures of Fab fragments for both antibodies were determined (at 2.8 Å and 2.0 Å resolution, respectively, for mAb806) (Fig. 3 and Table S1). In each case, the structures of each free and complexed Fab were essentially the same and the conformations of EGFR287–302 and the CDR loops of the antibodies were well defined. The epitope adopts a β-ribbon structure, with one edge of the ribbon pointing toward the Fab and with V299 buried at the center of the binding site (Fig. 3 B and C). Both ends of the epitope were exposed to solvent, consistent with the ability of these antibodies to bind to longer EGFR peptides that include EGFR287–302.

3D Structure of EGFR287–302 with the Fab Fragments of mAb806 and mAb175. To understand the molecular details of how mAb175 and mAb806 recognize a subset of the wtEGFR molecules, crystal structures of Fab fragments for both antibodies were determined alone and in complex with the oxidized epitope, EGFR287–302 (at 2.8 Å and 1.59 Å resolution, respectively, for mAb175; and 2.2 Å and 2.0 Å resolution, respectively, for mAb806) (Fig. 3A and Table S1). In each case, the structures of each free and complexed Fab were essentially the same and the conformations of EGFR287–302 and the CDR loops of the antibodies were well defined. The epitope adopts a β-ribbon structure, with one edge of the ribbon pointing toward the Fab and with V299 buried at the center of the binding site (Fig. 3 B and C). Both ends of the epitope were exposed to solvent, consistent with the ability of these antibodies to bind to longer EGFR peptides that include EGFR287–302.

Of the 20 antibody residues in contact with the epitope, there are only 2 substitutions between mAb806 and mAb175 (Fig. 3 B and C and Fig. S1A). mAb175 contact residues are: light-chain S30, S31, N32, Y49, H50, Y91, F94, and W96 and heavy-chain D32, Y33, A34, Y51, S53, Y54, S55, N57, R59, A99, G100, and R101; the mAb806 contact residues are the same, with sequence differences for the light-chain, N30, and heavy-chain, F33. EGFR287–302 binds to the Fab through close contacts between peptide residues 293–302, with most of the contacts being between residues 297 and 302. Main chain atoms of residues 300 and 302 hydrogen bond to the Fab (Fig. 3C). Recognition of the epitope sequence occurs through side-chain hydrogen bonds to residues E293 (to H50 and R101 of the Fab), D297 (to Y51 and N57), R300 (to D32), and K301 (via water molecules to Y51 and W96). Hydrophobic contacts are made at G298, V299, and C302. These contacts are consistent with the fine epitope mapping study for mAb806/EGFR that showed that E293, G298, V299, and C302 are important for antibody binding (23).

The conformation of the epitope backbone between amino acids 293 and 302 was essentially identical in the Fab806 and Fab175 crystals (rmsd = 0.4 Å for Cα atoms in these residues). Although it is constrained by the disulﬁde bond, the N terminus of the peptide (287–292) does not make signiﬁcant contact in either antibody structure and the conformations of the peptide in this region differ signiﬁcantly. In the Fab806 complex, this peptide segment appears rather disordered (Fig. 3A). More interestingly, the conformation of the EGFR287–302 peptide in contact with the antibodies is closely related to the EGFR287–302 conformation observed in the backbone of the EGFR structures (24, 25). In the Fab175:EGFR287–302 complex, the rmsd in Cα positions to tethered EGFR (25) is 0.66 Å and to untethered EGFR (chain B) (24) is 0.75 Å (Fig. 3B and C). We also studied the solution conformation of 15N-labeled oxidized EGFR287–302 by NMR spectroscopy. Comparing assigned resonances with those for random coil (Fig. S4), the free peptide adopted essentially a random coil structure, not the β-ribbon as seen in wtEGFR (24), implying that the antibodies induce the wild-type conformation in the peptide epitope.

Why do mAb806 and mAb175 recognize a subset of EGFR conformations? We manually docked the Fab structure of mAb175 onto an extracellular domain of wtEGFR (tethered and untethered monomers) and D2–7EGFR models by superimposing EGFR287–302 from the mAb complex on that in the EGFR structures. D2–7EGFR models were made by truncation of the corresponding ectodomain conformer. For the D2–7EGFR, there were no significant steric clashes with the receptor. In the
Removing the EGFR 271–283 Disulfide Bond Increases mAb806 Binding.

Protein–disulfide bonds usually provide increased structural rigidity, but in some cell surface receptors, particularly those for cytokines and growth factors, transient breaking of disulfide bonds and disulfide exchange can control the receptor’s function (26). We mutated either or both of the EGFR cysteine residues at positions 271 and 283 to alanine residues (C271A/C283A). The vectors capable of expressing full-length EGFR(C271A), EGFR(C283A), or EGFR(C271A/C283A) were transfected into the IL-3-dependent BaF/3 cell line. Stable BaF/3 clones that expressed the mutants at normal levels, i.e., <10⁶ per cell, were selected. The wtEGFR reacts poorly with mAb806; however, all of the cysteine mutants bound mAb806 strongly (Fig. 5A and Fig. 5B). Because these cysteine mutants also bound mAb528, they must be displayed on the cell surface with at least their L2 domain folded correctly. Quantitatively, mAb806 only recognized a small proportion of the total wtEGFR expressed on the surface of BaF/3 cells (the mAb806/528 binding ratio is 0.07). In contrast, mAb806 recognizes all of the EGFR(C271A/C283A) displayed on the cell surface (the mAb806/528 binding ratio is 1.01 ± 0.13).

Western blotting analysis confirmed that the EGFR(C271A/C283A) mutant is expressed at similar levels to the wtEGFR and is tyrosine phosphorylated in response to EGF stimulation (Fig. 5B). Further-
more, mutation of the 2 cysteines did not compromise EGF binding or receptor function: Ba/F3 cells expressing the EGFR<sub>C271A/C283A</sub> mutant proliferate in the presence of EGF (Fig. 5C). We have reproducibly observed that the Ba/F3 cells expressing the EGFR<sub>C271A/C283A</sub> mutation respond to lower concentrations of EGF, suggesting either higher affinity for the ligand or enhanced signaling potential for the mutant receptor. mAb806 has no effect on the in vitro EGF-induced proliferation of Ba/F3 wtEGFR cells, whereas mAb528 strongly inhibited the EGF-induced proliferation of these cells (Fig. 5D Left). In contrast, mAb806 totally ablated the EGF-induced proliferation in Ba/F3 EGFR<sub>C271A/C283A</sub> cells (Fig. 5D Right).

**Discussion**

When the EGFR or erbB2 are over-expressed or mutated in tumors, antibodies such as cetuximab, panitumumab, and herceptin that target EGFR family members are important options for treatment (3). The 3D structures of both the target receptor (1) and the antibody:receptor complexes (25, 27, 28) have improved our understanding of how these antibodies interfere with receptor activation. Studies such as these have also suggested that targeting other epitopes on this receptor family may produce new opportunities for using combinations of antibodies to improve cancer treatment. A drawback, however, with all currently approved therapeutic anti-EGFR antibodies is that they recognize the wtEGFR that is expressed in normal tissues including skin, liver, and gut. Not only does this pool of EGFR in normal tissue represent a large sink for the antibodies, it makes the use of antibody/cytotoxic conjugates impractical. Despite these limitations, it should be noted that the EGFR in many normal tissues (e.g., liver) appears not to be activated, so neutralizing anti-EGFR antibodies do not have a profound effect on vital homeostatic signaling (29). Many tumors contain over-expressed, mutated, or activated EGFR. Importantly, activated EGFR is functionally involved in the maintenance of the tumorigenesis state by enhancing cell movement, proliferation, invasion, angiogenesis, and survival of tumor cells. Consequently, the administration of anti-EGFR antibodies or EGFR kinase inhibitors can decrease the growth and survival of the tumor cells.

Antibodies directed to the unique junctional peptide in the D2–7EGFR have the potential to target several tumor types, including gliomas (29), without the difficulties associated with normal tissue uptake. However, the expression of the D2–7EGFR is infrequent, compared with over-expression of the wtEGFR, and antibodies targeting just D2–7EGFR will not necessarily inhibit over-expressed wtEGFR (30). mAb806 and mAb175 not only bind this truncated receptor, but also bind to over-expressed wtEGFR. These antibodies recognize an epitope contained within a cysteine loop (amino acids 287–302) that is accessible in the D2–7EGFR, but not in the wtEGFR, when expressed at low to moderate levels on cells in the absence of ligands (13). A previous attempt to predict how mAb806 bound its epitope in the context of the EGFR was not successful (19). Despite the generation of 3 models, the unusual change in accessibility of the epitope confounded the prediction algorithms, so it was not possible to use the predicted structures to improve our understanding of mAb806 binding to the wtEGFR.

Our structural studies with the EGFR<sub>C271A/C283A</sub> epitope show that both mAb806 and mAb175 recognized the same 3D structural motif in the wtEGFR structures (24, 25), suggesting that this backbone conformation also occurs in and is exposed in the D2–7EGFR. Critically, however, the orientation of the epitope in these structures would prevent antibody access to the relevant amino acids. This orientation is consistent with the experimental observation that mAb806 does not bind wtEGFR expressed on the cell surface at physiological levels. Detailed inspection of the EGFR structure raised another intriguing possibility. The EGFR<sub>287–302</sub> epitope lies against a second disulfide-bonded loop (amino acids 271–283), and we predicted that the disruption of this disulfide bond would allow access to the EGFR<sub>287–302</sub> loop without changing its backbone conformation (Fig. 4). Our results with the EGFR<sub>C271A/C283A</sub> mutant indicate that the CR1 domain can open up to allow mAb806 and mAb175 to bind stoichiometrically to this mutant receptor. This mutant receptor can still adopt a native conformation because it is fully responsive to EGF stimulation but, unlike the wtEGFR, is fully inhibited by mAb806. If a misfolded form of the EGFR with this disulfide bond broken were to exist on the surface of cancer cells, our data clearly shows it would be capable of initiating cell signaling and should be inhibited by either mAb806 or mAb175.

There is a second potentially more likely possibility to explain the binding of these antibodies. During ligand activation, the structural rearrangement of the receptor could induce local unfolding in the vicinity of the epitope, allowing the receptor to adopt a conformation that permits binding. In crystal structures, the epitope lies near the physical center of the EGFR ectodomain and access to the epitope is blocked by both the folded CR1 domain and the quaternary structure of the EGFR ectodomain. In the tethered and the untethered conformations, the integrity of the CR1 domain is stabilized by additional interactions with either the L1.ligand:L2 domains (untethered) or the L2:CR2 domains (tethered). However, the epitope region has some of the highest thermal parameters found in the ectodomain; the mAb806/175 epitope is structurally labile. During receptor activation, when the receptor undergoes a transition between the tethered and untethered conformations, it appears that mAb806 and mAb175 can access the epitope. Thus, at the molecular level, these mechanisms could contribute to the negligible binding of mAb806 and mAb175 to normal cells and the substantially higher levels of binding to tumor cells that have overexpressed and/or activated EGFR.

The mAb806 and mAb175 reactivity to a locally misfolded region of its target protein suggests the possibility of generating antibodies to other overexpressed/misfolded receptors for cancer therapeutics. For other members of the EGFR family, one approach would be to use the disulide mutants equivalent to EGFR<sub>C271A/C283A</sub> as immunogens because this would increase exposure of the equivalent epitope in an appropriately folded form. Under glycosylation or kinase, mutations of EGFR also increase mAb806 epitope accessibility and would provide alternate immunization strategies. More generally, in tumor cells that overexpress other growth factor receptors, in particular receptors with disulfide-rich domains (e.g., the insulin-like growth factor receptors [IGFRs], we predict that a proportion of these receptors will be partially misfolded because of factors such as under glycosylation or transiently mismatched or unfolded disulfide bonds. Thus, it is conceivable that other disulide mutant or truncated receptors could be used as immunogens to generate tumor-specific anti-receptor antibodies for use in cancer treatment.

**Materials and Methods**

**Cell Lines.** The Δ2–7EGFR transfected U87MG, Δ2–7 (10), the A431 (31), and the hormone-independent prostate DU145 (21) cell lines were grown as previously described (16). For site-directed mutants, Ba/F3 cell lines expressing different EGF receptors were maintained as reported earlier (32).

**Antibodies, Fabs, and Peptides.** Sequences of the mAb variable domains were determined from cDNAs, with corrections from the crystal structures. mAb806 and mAb175 were produced in the Ludwig Institute for Cancer Research Biological Production Facility, Melbourne. Intact mAbs were digested with activated papan at 37°C at a ratio of 1:20 and the papan inactivated with lidoacetaemide. The digestion was passed over Protein A Sepharose (Amersham) and concentrated using a 10,000 molecular weight cutoff (MWCO) centrifugal concentrator (Millipore). For Fab–peptide complexes, a molar excess of lyophilized peptide was added directly to the Fab and incubated for 2 h at 4°C before setting up crystallization trials. The EGFR<sub>C271A/C283A</sub> was synthesized using Fmoc chemistry, purified by RP-HPLC, and characterized by MS analysis.
Immunoprecipitation and Western Blotting. Cells were lysed using 1% Triton X-100, 30 mM Hepes, 150 mM NaCl, 500 mM 4-(2-aminoethyl) benzene sulfonyl fluoride, 150 mM aprotinin, 1 mM E-64 protease inhibitor, 0.5 mM EDTA, and 1 mM leupeptin (pH 7.4) for 20 min, clarified by centrifugation at 14,000 × g for 30 min, immunoprecipitated with the relevant antibodies at a final concentration of 5 μg/ml for 60 min, and captured by Sepharose-A beads overnight. Samples were then eluted with 2X NuPAGE SDS Sample Buffer (Invitrogen), resolved on NuPAGE gels, electro-transferred onto Immobilon-P transfer membrane (Millipore), and then probed with the relevant antibodies before detection by chemiluminescence radiography.

Surface Plasma Resonance. Using BiACore 3000, EGFR fragments were immobilized on a CMS sensor chip using amine, thiol, or Pms coupling at a flow rate of 5 μl/min (33). The mAbB06 and mAbB17 were passed over the sensor surface at a flow rate of 5 μl/min at 25 °C. K0 values were calculated from equilibrium binding data obtained by passing different concentrations of antibody over the sensor surfaces. Equilibrium binding data were analyzed in Scatchard format (Ref[Eq. C4]), where R is the sensorgram signal at equilibrium and C is the concentration (nM). The data were fitted using linear regression.

Xenograft Models. U87MG, Δ2–7 or DU145 cells (3 × 106) in 100 μl of PBS were inoculated s.c. into both flanks of 4- to 6-week-old female BALB/c nude mice (Animal Research Centre). All studies were conducted using established tumor models as reported previously (16). Data are expressed as mean tumor volume ± SE for each treatment group. Data were analyzed for significance by one-sided t tests where P < 0.05 was considered statistically significant. This research project was approved by the Animal Ethics Committee of the Austin Health, Helderberg, Australia.

Generation and Characterization of Stable Cells Expressing EGFR Mutant Constructs. The template for each mutagenesis was the human wtEGFR CDNA (GenBank accession number x00588) (31). Mutations were generated using a site-directed mutagenesis kit (Stratagene) and verified by automated nucleotide sequencing of each construct. Wild-type and mutant (C173, C281, and C173A/C281A) EGFR were transfected into BaF3 cells by electroporation, and stable cell lines were obtained as described previously (18). Methods for FACS analysis, EGFR induced proliferation assays, and analysis of EGFR activation by immunoblotting of BaF3 cells expressing variants of the EGFR have been extensively described in earlier manuscripts (18, 24).

Crystal Structure Determinations. Crystals were grown using a Topaz crystallization system (Fluidigm) and by hanging drop vapor diffusion from a 1:1 mixture of protein (7–10 mg/ml) and precipitant solutions, comprising: 0.15 M sodium formate for Fab175-P, 0.15 M sodium formate for FabB06-P; 0.2 M ammonium acetate for Fab175, 16–18% PEG6000 monomethylether for the FabB06-P peptide; 0.4 M NaI, 16% PEG6000, 0.1 M Mes pH 6.0 for Fab175 alone; 0.1 M sodium acetate at pH 4.6, 6–8% PEG6000, and 15–20% isopropanol for FabB06. Further details are in SI. Just before data collection, crystals were transferred to a cryoprotectant solution, consisting of reservoir supplemented with 25% glycerol (10% for FabB06 and 3% additional PEG6000), then mounted in a nylon loop and flash frozen directly into liquid nitrogen.

Diffraction data were collected using a Rigaku R-Axis IV detector on a Micromax-007 generator fitted with AXO optics or at beamline X29, NSLS synchrotron, and processed with CrystalClear or HKL2000, respectively. Structures were solved by molecular replacement with MOLREP (34), using pairs of V or C domains from PDB:12EB for FabB06 alone, then FabB06 for the other structures. Refinement was performed with PHACs (35) converged with R = 0.211 and Rfree = 0.263 for FabB06, R = 0.211 and Rfree = 0.273 for Fab806 peptide, R = 0.210 and Rfree = 0.305 for Fab175, and R = 0.199 and Rfree = 0.250 for Fab175 peptide. Data statistics are shown in Table S1.

Acknowledgments. We thank Colin Watson for valuable advice; Peter Czabotar, Marc Kvanasaki, and Peter Colman for collecting some data at the National Synchrotron Light Source (NSLS), Upton, NY; the staff at beamline X29 for their assistance; and the Australian Synchrotron Research Program and the U.S. Department of Energy for providing access. This work was supported in part by National Health and Medical Research Council Program Grant 280912 and Project Grant 433615 and National Institutes of Health Grant CA96504, W.D.F. and T.P.J.G. are supported by National Health and Medical Research Council Fellowships, W.K.C. is supported in part by National Cancer Institute-National Institutes of Health Grant CA95616 and is a fellow of the National Foundation for Cancer Research.

10. Luwor RB, et al. (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the del-2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61:5355-5361.